For this phenotype, a diverse range of antibodies (paraneoplastic and non-paraneoplastic) could be considered, starting with those more common with higher cancer risk (such as PCA-1 [ovarian and breast adenocarcinoma associated], PCA-Tr and metabotropic glutamate receptor [mGluR]-1, which are both lymphoma associated), while research-based testing could be considered for the less common and infrequently cancer-associated analytes (such as inositol triphosphate receptor [ITPR]-1 and septin-7 antibodies) [25, 48–51]. This evidence concerns the gene ITPR1 and cancer.